The increasing number of clinical diseases involving pathological contributions of the complement system has prompted renewed interest in therapeutic options to modulate this host defense pathway. Based on these findings, the pharmaceuticalRead More…
Advances in Complement System Targeted Therapy in Neurological Diseases
The complement system, a vital component of innate immunity and a potent promoter of inflammation, has a crucial role in host defense against pathogens and the development of central and peripheral nervousRead More…
Successful Expansion of Complement Drugs into the Market for Major, Chronic, and Common Diseases
On February 17, 2023, Apellis announced the FDA approval of Pegcetacoplan, a complement C3 inhibitor, as the first molecularly targeted drug for the treatment of dry AMD or geographic atrophy. This approvalRead More…
Complement C5 Inhibitor Receives Priority Review by the FDA for Geographic Atrophy
On February 16, Iveric Bio announced in an announcement that the New Drug Application (NDA) for the complement C5 inhibitor Zimura (avacincaptad pegol, ACP) for the treatment of age-related macular degeneration (AMD)Read More…
Application of Nucleic Acid Aptamers in Tumor Immunotherapy
Nucleic Acid Aptamer Nucleic acid aptamers are single-stranded DNA or RNA (ssDNA or ssRNA) that are able to bind specifically to target molecules by folding to form a unique tertiary structure. TheRead More…
Cell sub-journal: Mechanism of conversation between sphingolipid signaling and complement signaling for cancer metastasis revealed
In a new study, researchers have identified a series of molecular interactions that may be key to stopping the spread of cancer cells. The new study identifies, for the first time, aRead More…
Why do certain people require a complement check during a renal function test?
The human immune system’s most crucial element is the complement, and its two most essential subtypes are C3 and C4. Low levels of the two subtypes indicate that the immune system ofRead More…
A Ground-Breaking Complement Therapy for Geographic Atrophy (GA) Announced by Iveric Bio
On November 3, 2022, Iveric Bio announced that it had submitted the first part of the “rolling review” for the new drug application (NDA) of avacincaptad pegol (ACP, also known as Zimura)Read More…
First Potential Oral Monotherapy for Paroxysmal Nocturnal Hemoglobinuria
Novartis recently announced that its new drug iptacopan has achieved positive results in a Phase 3 clinical trial for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), with patients’ hemoglobin levels increasing significantlyRead More…
Acetylcholine Receptor (AChR) Antibody-positive Myasthenia Gravis, from Antibody to Complement
Myasthenia gravis (MG) is an autoimmune disease characterized by an acquired neuromuscular junction transmission disorder mediated by autoantibodies. MG patients are mainly characterized by fluctuating weakness and fatigue of skeletal muscles, withRead More…